CRC Research Update

  • REGULATORY

    ESMO Updates Guidelines for Metastatic Colorectal Cancer

    New ESMO Clinical Practice Guidelines establish structured treatment algorithms driven by MMR/MSI status, ECOG performance, tumor location, and extended molecular profiling including RAS, BRAF, HER2, and KRAS G12C. Key updates include first-line FOLFOX-encorafenib-cetuximab for BRAF V600E-mutated tumors and ctDNA-guided anti-EGFR rechallenge in refractory settings. (Annals of Oncology / OncoDaily)

  • TRIAL DATA

    Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC

    Research comparing dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H (microsatellite instability-high) metastatic colorectal cancer. (Clinical Colorectal Cancer)

  • RESEARCH

    KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy

    Preclinical research shows that KRAS G12D inhibition with MRTX1133 remodels the tumor immune environment by reducing immunosuppressive cells and facilitating infiltration of natural killer and CD8+ T cells, reversing systemic immunosuppression and restoring fitness of adoptively transferred NK cells. (Science Advances)

  • SCREENING

    Childhood Cancer Survivors Underutilize Colorectal Cancer Screening

    A French national study found that childhood cancer survivors participated in fecal immunochemical testing at rates of 20.0% to 23.2% across three screening periods—significantly lower than the general population—despite their elevated CRC risk. (International Journal of Epidemiology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

💙 Living with CRC

Survivorship, quality of life, and supportive care

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Today's research highlights progress across treatment guidelines, immune-based therapies, and understanding the unique needs of diverse patient populations.